NASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis $7.96 -0.12 (-1.43%) As of 11:56 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immix Biopharma Stock (NASDAQ:IMMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immix Biopharma alerts:Sign Up Key Stats Today's Range$7.66▼$8.3850-Day Range$7.20▼$13.9152-Week Range$3.56▼$15.10Volume313,551 shsAverage Volume1.31 million shsMarket Capitalization$569.10 millionP/E RatioN/ADividend YieldN/APrice Target$23.86Consensus RatingModerate Buy Company Overview Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues.The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use.Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.AI Generated. May Contain Errors. Read More Immix Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreIMMX MarketRank™: 2.42557377049 of 5 starsImmix Biopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 457th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingImmix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmix Biopharma has a consensus price target of $23.86, representing about 195.6% upside from its current price of $8.07.Amount of Analyst CoverageImmix Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immix Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immix Biopharma are expected to decrease in the coming year, from ($0.76) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.57% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 9.24.Change versus previous monthShort interest in Immix Biopharma has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentImmix Biopharma has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immix Biopharma this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.26% of the stock of Immix Biopharma is held by institutions.Read more about Immix Biopharma's insider trading history. Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMX Stock News HeadlinesImmix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12 at 11:32 PM | marketscreener.comMImmix Biopharma Reports Positive NEXICART-2 Data, Advances Commercial Readiness and Third Quarter 2026 Financial ResultsNovember 12 at 4:31 PM | quiverquant.comQTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 13 at 1:00 AM | USA Capital Gold (Ad)Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNovember 12 at 4:15 PM | globenewswire.comImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026November 4, 2026 | markets.businessinsider.comImmix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026November 4, 2026 | globenewswire.comImmix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst RevisionsOctober 21, 2026 | finance.yahoo.comImmix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceOctober 5, 2026 | globenewswire.comSee More Headlines IMMX Stock Analysis - Frequently Asked Questions How have IMMX shares performed this year? Immix Biopharma's stock was trading at $5.23 at the beginning of the year. Since then, IMMX stock has increased by 54.3% and is now trading at $8.07. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share. Who are Immix Biopharma's major shareholders? Top institutional shareholders of Immix Biopharma include State Street Corp (4.62%), Aberdeen Group plc (1.14%), Profund Advisors LLC (0.04%) and C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors (0.04%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris and Carey Ng. View institutional ownership trends. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immix Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Biofrontera (BFRI), Genprex (GNPX) and Intel (INTC). Company Calendar Last Earnings11/12/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IMMX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMX CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees21Year Founded2012Price Target and Rating Average Price Target for Immix Biopharma$23.86 High Price Target$30.00 Low Price Target$19.00 Potential Upside/Downside+204.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.44% Return on Assets-34.72% Debt Debt-to-Equity RatioN/A Current Ratio25.13 Quick Ratio25.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book4.43Miscellaneous Outstanding Shares71,540,000Free Float49,863,000Market Cap$561.09 million OptionableOptionable Beta0.29 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:IMMX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
